PRF Technologies (PRFX) announced that the FDA has cleared the company’s investigational new drug application for OcuRing-K, enabling the initiation of a Phase II clinical trial in patients undergoing cataract surgery.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRFX:
- PRF Technologies Posts 2025 Results as LayerBio and DeepSolar Deals Drive Dual-Platform Pivot
- PRF Technologies Taps Blade Ranger to Drive Utility-Scale DeepSolar Deals
- PRF Technologies signs commercial collaboration agreement with Blade Ranger
- PRF Technologies Reshapes Top Leadership With New Interim CEO and Permanent CFO